Skip to main content

Access Inks Delivery Technology-Evaluation Deal with Undisclosed Pharma

Premium

Access Pharmaceuticals this week announced that it has signed a deal under which its CobaCyte and CobOral siRNA delivery technologies will be evaluated by an undisclosed pharmaceutical company.

The delivery approaches are based on Access' so-called Cobalamin technology, which takes advantage of the body's natural vitamin B12-uptake mechanism. A polymer and an siRNA are joined to make a nanoparticle, which is then coated with the vitamin.

According to Access, it will provide oral and intravenous siRNA formulations to the pharmaceutical firm for evaluation.

Successfully developed compounds will be subject to a formal licensing agreement, Access noted.

Additional terms were not disclosed. The deal follows a similar arrangement Access forged earlier in the year (GSN 4/14/2011).

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.